Syndax crossed $100 million in combined quarterly net sales for the first time in Q1 2026, but the number that reframes the entire commercial story is smaller: 48%. That is the share of R/R KMT2A-translocated patients now proceeding to stem cell transplant after receiving revumenib — up sharply from a prior estimate of 33%. The strategic implication is direct. Post-transplant patients are candidates for maintenance therapy, meaning Syndax has quietly engineered a second revenue event out of the same diagnosed population. Duration of treatment extends, and the addressable pool deepens without requiring a single new label.
The revenue split tells its own story. Revuforj posted $48.9 million — 144% above Q1 2025 — while Niktimvo generated $55.1 million in net sales, of which Syndax captures only $15.9 million as collaboration revenue through its partnership with Incyte. That asymmetry matters for how investors should model the business. Revuforj is a wholly owned asset with full economics; Niktimvo’s commercial momentum benefits Incyte’s P&L more than Syndax’s. The company is effectively running two commercial products but capturing the full upside on only one. Profitability math therefore rests disproportionately on revumenib’s trajectory, which makes the frontline pivotal trials — EVOLVE-2 in unfit patients and REVEAL-ND in intensive chemotherapy — the actual valuation fulcrum, not the current R/R revenues.
Two Q4 2026 data readouts add a separate strategic dimension: Phase 2 topline results for axatilimab in both newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis. IPF is a brutal, high-unmet-need market that Roche, Boehringer Ingelheim, and a crowded pipeline are already contesting. A positive signal there transforms Niktimvo from a niche GVHD asset into a broader fibrotic disease franchise — and immediately invites questions about whether Incyte’s collaboration structure remains the right vehicle or whether Syndax becomes a acquisition target at a structurally higher valuation. Failure, conversely, concentrates everything back onto hematology.
The single marker worth tracking is revumenib’s transplant-to-maintenance conversion rate as real-world post-HSCT data arrive in Q2. If that rate holds above 40% in practice, the duration-of-therapy thesis becomes durable revenue rather than investor narrative, and the frontline trials are building on a foundation that already pays.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
